U.S. FDA Grants Phosphate Inositol-3-Kinase (PI3K) Inhibitor umbralisib (TGR-1202) Orphan Drug Qualification
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, TG
(http://announced that the U.SFood andDrug(http://Administration (
FDA(http://) has granted the phosphate inositol-3-kinase (PI3K) inhibitor umbralisib (PiGR-1202) orphan drug for the treatment of all three types of marginal area lymphoma (M-Spleen) patients: lymph nodesin January, the FDA also granted the umbralisib treatment to a recurrent or refractory MZL adult patient who has received at least one anti-CD20 therapy (BTD)Umbralisib is an oral, daily PI3K inhibitor that uniquely suppresses CK1-s, which may enable it to overcome some of the tolerable problems associated with the first generation of PI3K inhibitorsIn addition to umbralisib, TG is also developing a mono-resistant drug, ublituximab (TG-1101), a glycochemical-embedded IgG1 monoclonal antibody targeted at CD20, which is being evaluated in five post-clinical studies for the treatment of cancer (chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) and non-cancer (multiple myeloidas) (MM), TG is waiting for key data from these studiesTG recently advanced its PD-L1 mono-anti-TG-1501 and its co-valence in combination with Bruton tyrosine kinase (BTK) inhibitor TG-1701 to Phase I clinical development, and plans to advance more pipeline assets to clinical in the future
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
